When: Nov 17 2020 at 12:00 EST / 18:00 CET – Where: Online. Free / RSVP with Registration Form Below
Update: the webinar took place this Nov 17 – see a replay at this link.
For this third webinar, we are pleased to welcome the esteemed Roland Derwand, MD, MBA, from Munich Germany.
The webinar will mostly focus on the study titled “COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study” he co-authored with Dr Martin Scholz, PhD, and Dr Vladimir Zelenko. The study is now peer-reviewed and accepted as pre-proof in the International Journal of Antimicrobial Agents.
Dr Derwand will present how the study was conducted and what are the most salient points one needs to draw from it. He will put particular emphasis on the role of Zinc – an agent that Dr Zelenko included very early on in his treatment protocol, and which is now widely recognized as essential for the early treatment of COVID-19.
Dr Derwand will also comment on the situation with COVID-19 in Germany and the therapeutic approaches the country has adopted to fight the disease. For the Q&A session, we hope that Prof Martin Scholz will be able to join Dr Derwand.
About Roland Derwand, Dr. med., MBA
Dr Derwand holds a medical degree from the University of Mainz in Germany. He did internships at Baylor College of Medicine in Houston, Texas, and at Western University, in London Ontario. For his doctorate in cardiovascular physiology he received an award by the Boehringer Ingelheim Foundation. Dr. Derwand worked as post-doc in physiology and cardiology at the Ludwig Maximilan University of Munich. Three years he was honorary advisory board member at the Center for Thrombosis and Hemostasis of the University Medical Center Mainz and honorary lecturer for life sciences in Munich. He also completed an MBA at the PFH Superior School of business in Göttingen.
Dr Derwand has worked in various capacities for several corporations in national and international positions, including Servier, Daiichi Sankyo Europe, Leukocare, and Alexion Pharmaceuticals – a company where he presently holds the position of Executive Director for Medical Affairs DACH.
While pursuing a mostly corporate career, Dr Derwand co-authored a range of academic articles, in journals such as Medical Hypotheses, Biotechnology Journal, Immunological Investigations, Cancer Cell International, and Circulation.
His research along with Dr Scholtz during the COVID-19 pandemic, including the work of Dr Zelenko, was made independently, on his own time, and for his presentation, he will share his perspectives and not those of his employer.
Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today’s battle against COVID-19?
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study
This is a free webinar, yet to access it, you need to register in advance. The access codes for viewing the webinar and being able to ask your questions will be emailed the day prior to the event.